Replies to post #114709 on Biotech Values

[biomaven0]

some investors thought Roche/IMGN’s T-DM1 data were spectacular

I didn't see their trial being stopped early for efficacy. I'd say their data was very good but nowhere near spectacular.

I can't say I understand the FDA's reluctance in their case and it certainly does give pause to anyone looking for accelerated approval for a condition with lots of existing alternative treatments.

Peter